Objectives: With increasing treatment choices for inflammatory bowel disease (IBD), patients' preferences should be considered to limit non-adherence. We explored patients' preferences for route, form and frequency of medication administration, and factors influencing these choices. Methods: Patients rated acceptability of different forms of medication on 10-point Likert scales and preferences for highest acceptable frequency. Results: Of 298 patients significantly more found tablets (91%) to be highly acceptable compared to granules (64%), infusions (33%) and subcutaneous injections (34%; p < 0.0001). The acceptable frequency for tablets was considered as daily by 63.5% and several times daily by 32.3%. Participants preferred nurse delivered over self-administered injections (median score 8 vs 5, p < 0.0001) and hospital-based infusions over infusions at home (median score 7 vs 5, p = 0.001). Patients with previous or current anti-TNF exposure were more accepting of self-administered injections (50.5% vs 23.3% anti-TNF naive; p < 0.001), more accepting of home based infusions (43.7% vs 28.0%; p = 0.001) and more accepting of hospital-based infusions (57.2% vs 37.8%; p = 0.02). Conclusion: Most patients with IBD prefer tablets. Those patients who already experienced biological agents, had a high level of acceptance for subcutaneous and intravenous forms of medication.
Objectives: With increasing treatment choices for inflammatory bowel disease (IBD), patients' preferences should be considered to limit non-adherence. We explored patients' preferences for route, form and frequency of medication administration, and factors influencing these choices. Methods: Patients rated acceptability of different forms of medication on 10-point Likert scales and preferences for highest acceptable frequency. Results: Of 298 patients significantly more found tablets (91%) to be highly acceptable compared to granules (64%), infusions (33%) and subcutaneous injections (34%; p < 0.0001). The acceptable frequency for tablets was considered as daily by 63.5% and several times daily by 32.3%. Participants preferred nurse delivered over self-administered injections (median score 8 vs 5, p < 0.0001) and hospital-based infusions over infusions at home (median score 7 vs 5, p = 0.001). Patients with previous or current anti-TNF exposure were more accepting of self-administered injections (50.5% vs 23.3% anti-TNF naive; p < 0.001), more accepting of home based infusions (43.7% vs 28.0%; p = 0.001) and more accepting of hospital-based infusions (57.2% vs 37.8%; p = 0.02). Conclusion: Most patients with IBD prefer tablets. Those patients who already experienced biological agents, had a high level of acceptance for subcutaneous and intravenous forms of medication.
Authors: Jan Marsal; Manuel Barreiro-de Acosta; Irina Blumenstein; Maria Cappello; Thomas Bazin; Shaji Sebastian Journal: Front Med (Lausanne) Date: 2022-06-15
Authors: E H J Savelkoul; M H J Maas; A R Bourgonje; F Crouwel; V B C Biemans; N den Broeder; M G V M Russel; T E H Römkens; N K de Boer; G Dijkstra; F Hoentjen Journal: J Crohns Colitis Date: 2022-09-08 Impact factor: 10.020
Authors: Gemma Burdge; Alice Hardman; Isabel Carbery; Giacomo Broglio; Dan Greer; Christian P Selinger Journal: J Clin Med Date: 2022-09-26 Impact factor: 4.964